Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Expects Increasing Flow Of Adverse Event Reports

Executive Summary

FDA expects the Center for Drug Evaluation & Research to receive 17% more adverse reaction reports in fiscal year 2006 than it received in FY 2004
Advertisement

Related Content

Serious Adverse Event Periodic Reporting Increased 20% In 2004, FDAer Says
Serious Adverse Event Periodic Reporting Increased 20% In 2004, FDAer Says
FDA Unveils Rx Safety Board, Website; Postmarket Surveillance Overhaul Next
FDA Unveils Rx Safety Board, Website; Postmarket Surveillance Overhaul Next
FDA Expects Faster Reviews, Fewer Approvals In Fiscal Years 2005, 2006
FDA Expects Faster Reviews, Fewer Approvals In Fiscal Years 2005, 2006
FDA Expects Faster Reviews, Fewer Approvals In Fiscal Years 2005, 2006
Drug Safety Changes Should Await IoM, HHS Secretary Tells Congress
Detour On FDA’s “Critical Path:” Safety Issues Divert Agency’s Attention
IoM Drug Safety Study May Buy Time For FDA; Report Will Play In PDUFA IV

Topics

Advertisement
UsernamePublicRestriction

Register

PS045368

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel